Combination Use of Triamcinolone Acetonide and Immunotherapy as a New Therapeutic Option in Alopecia Totalis

The study evaluated the combination of triamcinolone acetonide (TA) injections and immunotherapy (SADBE or DPCP) in treating alopecia totalis (AT) with body hair loss in 10 patients (1 male, 9 females, aged 12-43) who did not initially respond to immunotherapy. Monthly TA injections resulted in a 10% complete response rate and a 60% partially good response rate. Good responders exhibited hair follicle anagen stages and vellus hair development, enhancing susceptibility to subsequent immunotherapy and leading to more hair regrowth. Although the complete response rate was low, the combination therapy showed potential for hair cycle recovery in AT patients.